Black Diamond Therapeuticの空売り状況は、投資家がBlack Diamond Therapeuticの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Black Diamond Therapeutic (NASDAQ:BDTX) 株価情報, 空売り情報

Black Diamond Therapeutic

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutics Inc

Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) today announced that its Board of Directors has appointed W. Paul Bowers as its Independent Board Chair, effective April 29. Mr. Bowers has been an Independent Director on Exelon's Board since 2021. The change comes at the retirement of outgoing Board Chair, John F. Young, who has served in the role since 2022.
 &nbsp;

News

Management

Exelon Board Appoints Paul Bowers As Independent Board Chair, Effective April 29

Major Wall Street investment banks are divided over how the dollar will move from here, yet much clarity could be just days away as a deluge of <a href="https://www.benzinga.com/news/econ-s">key economic data looms.</a>
In an outlook shared with clients last week, Wells Fargo's economics team, led by Nick Bennenbroek, expressed a bullish short-term stance on the U.S. dollar, calling the recent wave of depreciation &#8220;tactical&#8221; rather than the beginning of a structural trend.
"We expect the U.S. dollar to rebound in the immediate period ahead," the analysts said, suggesting the dollar will remain fundamentally supported before resuming trend strength into 2026.
<h3 class="wp-block-heading">Bearish Positioning Builds As Speculators Eye US Economic Weakness</h3>
 Speculative net short positions against the greenback — measured across 10 major currencies and the Dollar Index (DXY) — surged to $40 billion last week, the highest level since October 2023, according to Commodity Futures Trading Commission data.
The Dollar Index, as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), has dropped 8% year-to-date, reaching its most oversold levels since December 2020 last week.
Technically, it is now 5.5% below its 200-day and 4.5% below its 50-day moving averages, underscoring how aggressive the recent selloff has been.
Wells Fargo indicated that unusual dynamics are pressuring the dollar, particularly the political noise and tariff volatility emanating from the U.S. 
"With the source of policy uncertainty and volatility coming out of the United States, market participants have sold dollar-denominated assets and moved away from Treasuries," they said. 
Yet, the team described this as &#8220;a transitory phenomenon,&#8221; not a fundamental reassessment of U.S. assets.
<h3 class="wp-block-heading">Goldman Sachs Sees Further Dollar Weakness Ahead</h3>
Over at Goldman Sachs, foreign exchange analyst Kamakshya Trivedi took the opposite side of the trade.
"Even after a swift move in recent weeks, we believe that the dollar has further to fall," Trivedi said. 
The investment bank highlights that the underperformance of U.S. assets and the reduction in global investors' enthusiasm for unhedged dollar assets could trigger a longer-lasting decline in the greenback.
Trivedi emphasized that investors may be overestimating the impact of short-term positioning while underestimating the structural reallocation already underway. 
"We are more focused on the likely shift in future allocations," he said, citing historical parallels where changes in investor appetite led to persistent exchange rate moves.
Goldman's concern is compounded by ongoing uncertainty around U.S. trade and monetary policy. 
While President Donald Trump's recent statements hint at potential tariff rollbacks and efforts to reassure markets — including backing off pressure on the Fed — the bank is unconvinced these efforts will quickly restore investor confidence.
<h3 class="wp-block-heading">Dollar Direction Hinges On Upcoming Macro Data</h3>
The next few trading days could be decisive for the dollar&#8217;s short-term fate, with several high-impact U.S. economic reports on deck:
<ul>
<li>Q1 2025 GDP (Wednesday): Expected to slow sharply from 2.8% in Q4 2024 to 0.4%, according to median economist consensus tracked by TradingEconomics.</li>
<li>Personal Consumption Expenditure (PCE) price index (Wednesday): Fed's preferred inflation gauge expected to cool to from 2.5% to 2.2% in March, with core PCE dropping from 2.8% to 2.6%</li>
<li>April Jobs Report (Friday): Forecasts see nonfarm payrolls at 135,000, down from 228,000, with unemployment steady at 4.2%</li>
</ul>
If the data confirm a softening U.S. economy, it could validate Goldman Sachs' bearish thesis, especially as investors price in earlier and deeper Federal Reserve rate cuts. 
On the flip side, any surprise economic resilience in jobs or inflation could lend weight to Wells Fargo's tactical dollar rebound call.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Currency ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Dollar Under Pressure: Wall Street Split Widens Ahead Of High-Stakes US Data

Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) has seen its stock climb 50% to $1.34 over the past week following a series of company announcements.
What To Know: The California-based electric vehicle maker recently <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">appointed</a> founder YT Jia as Co-CEO alongside current CEO Matthias Aydt, signaling a new dual-leadership structure. Jia will oversee finance, legal and supply chain operations in addition to his current responsibilities. His new equity incentive package is tied to market cap and stock performance.
At the company's recent "FF Stockholder Community and FX Co-Creation Day" in Los Angeles, Jia outlined strategic goals including launching the first FX model by end of 2025, achieving positive gross margin and operating cash flow and pursuing global AI and AIEV M&amp;A initiatives. 
California <a href="https://www.benzinga.com/pressreleases/25/04/b45031191/faraday-future-receives-powerful-endorsements-from-california-politicians-supporting-ffs-global-au">political figures</a> including former Assembly Speaker Anthony Rendon and Hanford Mayor Lou Martinez expressed public support for the company's transformation efforts. 
Faraday Future emphasized its intent to maximize stakeholder value and resist illegal short-selling as it executes its Global Bridge Strategy.
Read Also: <a href="https://www.benzinga.com/news/25/04/45078865/d-wave-quantum-qbts-stock-falls-amid-valuation-critique-by-kerrisdale-capital">D-Wave Quantum Stock Falls Amid Valuation Critique By Kerrisdale Capital</a>
<h2 class="wp-block-heading">How To Buy FFAI Stock</h2>
By now you're likely curious about how to participate in the market for Faraday Future &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Faraday Future, which is trading at $1.33 as of publishing time, $100 would buy you 75.19 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, FFAI has a 52-week high of and a 52-week low of

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Faraday Future (FFAI) Shares Surge 50% Amid Leadership Changes And Strategic Updates

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beigene.com%2F&amp;esheet=54246103&amp;newsitemid=20250429590949&amp;lan=en-US&amp;anchor=BeiGene&amp;index=1&amp;md5=0c09798a0c67c852789b965c290809ae">BeiGene</a>, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.
On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA&#xAE; (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene's petition to institute the PGR. The USPTO's Final Written Decision is appealable by Pharmacyclics.
Commenting on the ruling, BeiGene General Counsel Chan Lee said: "We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today's decision reinforces our belief that Pharmacyclics' ‘803 patent is overly broad and invalid. BeiGene is confident in the strength of our intellectual property supporting BRUKINSA, a clearly differentiated and independently developed medicine. With approvals in more than 70 countries and regions for the treatment of multiple B-cell malignancies, BRUKINSA continues to set a new standard of care for patients worldwide."

USPTO Renders Final Decision, Invalidating All Challenged Pharmacyclics Patent Claims Against BeiGene

SoFi Technologies Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) stock price gained Tuesday after it reported its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45062395/sofi-reports-first-quarter-2025-with-record-net-revenue-of-772-million-record-member-and-product-g" rel="noreferrer noopener">first-quarter 2025</a> earnings on Tuesday. Here's a look at the&nbsp;key metrics from the quarter.
The company reported quarterly adjusted sales of $770.72 million, beating analyst estimates of $739.04 million. The company reported quarterly adjusted earnings of 6 cents per share, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating&nbsp;analyst estimates of</a> 4 cents per share.
Adjusted revenue rose 33% year-over-year. Financial services revenue increased by 101% year-over-year, lending segment revenue increased by 25% year-over-year, and technology platform revenue increased by 10% year-over-year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44989977/sofi-stock-is-up-11-this-week-whats-going-on" rel="noreferrer noopener">SoFi Stock Jumps as It Opens AI and Private Market Investments to Everyday Investors</a>
Net interest income of&nbsp;$498.7 million&nbsp;was up 24%&nbsp;year-over-year, driven by a&nbsp;23%&nbsp;growth in average interest-earning assets and an 82 basis points decrease in cost of funds.
SoFi added 800,000 new members in the quarter, bringing total members up to 10.9 million, up 34% year-over-year. Product additions totaled nearly 1.2 million in the quarter.
SoFi&nbsp;CEO&nbsp;Anthony Noto&nbsp;<a target="_blank" href="https://www.cnbc.com/2025/04/29/sofi-crypto-investing.html" rel="noreferrer noopener">told</a> CNBC in an interview Tuesday that the fintech bank will bring back cryptocurrency investing this year following a shift in the regulatory landscape under the Trump administration. It had to dump crypto investing in late 2023 to bag a bank charter.&nbsp;
Outlook: In the second quarter of 2025, SoFi expects to generate $785 million—$805 million of adjusted net revenue versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimates of</a> $783.02 million, $200 million—$210 million of adjusted EBITDA, $60 million—$70 million of GAAP net income and $0.05-$0.06 of GAAP EPS (below the estimate of $0.06).
For the full year 2025, the company expects adjusted net revenue of $3.235 billion-$3.310 billion (<a href="https://www.benzinga.com/25/01/43233747/sofi-q4-earnings-24-revenue-increase-adds-785k-members-ceo-highlights-strong-financial-services-momentum-projects-23-26-revenue-growth-for-2025" target="_blank" rel="noreferrer noopener">prior $3.200 billion-$3.275 billion</a>) versus analyst consensus of $3.200 billion, which equates to approximately 24%-27% (prior 23%-26%) year-over-year growth.
Sofi anticipates an adjusted EBITDA of $875 million-$895 million (prior $845 million-$865 million), GAAP net income of $320 million- $330 million (prior $285 million-$305 million), and GAAP EPS of $0.27-$0.28 (prior $0.25 to $0.27) versus consensus of $0.26. 
Price Action: SOFI stock is up 2.84% at $13.58 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in" target="_blank" rel="noreferrer noopener">Cramer Cautions on SoFi Stock After Weak 2025 Profit Outlook</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Fintech news covering the emerging Financial Technology services sector

Fintech

Guidance

Movers

Tech

SOFI

SoFi Stock Pops As Revenue Soars And CEO Teases Crypto Comeback

Vacasa, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) ("Vacasa" or the "Company"), a leading vacation rental management platform in North America, today announced that its stockholders have approved the proposed merger with Casago (the "Merger").
On April 29, 2025, Vacasa held a special meeting of the Company's stockholders (the "Special Meeting") to vote on a proposal (the "Merger Agreement Proposal") to adopt the Agreement and Plan of Merger, dated as of December 30, 2024, as amended by Amendment No. 1 thereto, dated as of March 17, 2025, and by Amendment No. 2 thereto, dated as of March 28, 2025. At the Special Meeting, approximately 69% of the Company's Class A common stock, 96% of the Company's Class B common stock and 72% of the Company's Class A common stock and Class B common stock, voting together as a single class, voted in favor of the Merger Agreement Proposal.
The Company expects closing of the Merger to occur at 11:59 pm ET on April 30, 2025, subject to the satisfaction or waiver of the remaining closing conditions.

VCSA

Vacasa Stockholders Approve Proposed Merger With Casago

Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares fell 13.2% to $12.85 during Tuesday&#8217;s session after the solar-grade polysilicon producer reported <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">worse-than-expected</a> first-quarter results, signaling possible industry struggles.
What To Know: The company posted an adjusted net loss of 80 cents per ADS, wider than analyst expectations of a 69 cent loss. Revenue dropped 70% year-over-year to $123.9 million, missing the $182.1 million consensus. The sharp decline was driven by lower sales volumes and weak pricing, amid persistent overcapacity and muted demand in the solar PV market.
Gross margin plunged to -65.8% from +17.4% a year ago, with a gross loss of $81.5 million. Polysilicon average selling prices dropped to $4.37/kg, below both production and cash costs. Despite losses, Daqo&#8217;s balance sheet shows $2.15 billion in liquid assets and <a href="https://www.benzinga.com/pressreleases/25/04/n45062964/daqo-new-energy-announces-unaudited-first-quarter-2025-results">no financial debt</a>.
CEO Xiang Xu said the company ran at 33% capacity to manage inventory and mitigate low prices. Looking ahead, Daqo expects second-quarter polysilicon output of 25,000–28,000 MT. Management remains confident in long-term prospects, citing cost leadership, new technologies and China&#8217;s push for solar expansion.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/45073201/plug-power-stock-is-trending-tuesday-whats-going-on">Plug Power Stock Is Trending Tuesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy DQ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Daqo New Energy&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DQ has a 52-week high of $30.85 and a 52-week low of $12.40.

Daqo New Energy (DQ) Stock Slides On Steep Revenue, Earnings Miss In Q1

Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) reported first-quarter financial results before the market open on Tuesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/n45062385/the-sherwin-williams-company-reports-2025-first-quarter-financial-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $5.31 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $5.4 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $2.25, versus estimates of $2.16 per share</li>
</ul>
Sherwin-Williams said total sales declined 1.1% year-over-year. Consumer Brands Group sales fell 6% year-over-year, primarily due to &#8220;soft&#8221; DIY demand in North America. Performance Coating Group sales were down 4.8% in the quarter. Paint Stores Group sales fared better, seeing 1.2% sales growth during the period, primarily driven by selling price increases. 
The company returned&nbsp;$552.1 million&nbsp;to shareholders in the first quarter in the form of dividends and repurchases. Sherwin-Williams ended the period with $199.8 million in cash and cash equivalents.
&#8220;In a demand environment that remained choppy as we anticipated, Sherwin-Williams continued to execute our strategy and delivered solid&nbsp;first quarter&nbsp;results driven by gross margin expansion and good cost control,&#8221; said Heidi Petz, chair, president and CEO of Sherwin-Williams.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45061797/us-stock-futures-edge-higher-tuesday-expert-warns-of-perfect-volatility-storm-with-major-earnings-and-economic-data-due-this-week">US Stock Futures Edge Higher Tuesday: Expert Warns Of &#8216;Perfect Volatility Storm&#8217; With Major Earnings And Economic Data Due This Week</a>
Guidance: Sherwin-Williams expects second-quarter revenue to be up or down in the low-single digit percentage range. The company guided for full-year 2025 net sales growth in the low-single digit percentage range. 
Sherwin-Williams also expects full-year adjusted earnings of $11.65 to $12.05 per share versus estimates of $11.90 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;We continue to expect demand softness to persist in several end markets well into the second half of the year. Regarding current tariffs, it&#8217;s important to remember that the largest portion of our revenue is in&nbsp;the United States, and the majority of our raw materials are sourced in the regions where we manufacture. In a macro-economic environment that remains turbulent, we are focused on being a source of stability and reliability for our customers, providing them with differentiated solutions that increase their productivity and profitability,&#8221; Petz said.
SHW Price Action: <a href="http://benzinga.com/quote/SHW">Sherwin-Williams shares</a> were up 5.46% at $350.33 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

Sherwin-Williams Reports Mixed Q1 Results In 'Choppy' Demand Environment

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">epidermolysis bullosa (RDEB)</a>.
RDEB is&nbsp;a severe, genetically inherited skin disorder characterized by blistering and skin fragility, often presenting at birth.
Zevaskyn is the only FDA-approved product to treat RDEB wounds <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061116/u-s-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-therapy-for-p" rel="noreferrer noopener">with a single application</a>.
Zevaskyn consists of a patient&#8217;s skin cells (keratinocytes) genetically modified to produce functional Type VII collagen. Zevaskyn sheets are surgically applied to the patient&#8217;s wounded areas. In a single application, up to 12 credit card-sized sheets can be combined to cover large areas or applied to multiple distinct wounds, allowing for significant coverage of affected body areas.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
Zevaskyn is expected to be available beginning in the third quarter of 2025 through Zevaskyn Qualified Treatment Centers.
The FDA approval is based on the pivotal Phase 3 VIITAL study, which met its two co-primary efficacy endpoints, demonstrating statistically significant healing of 50% or more from baseline in large chronic RDEB wounds and pain reduction from baseline as assessed by the Wong-Baker FACES scale, as evaluated at six months after treatment.
Across 43 large and chronic wounds treated with a single application of Zevaskyn, 81% of wounds showed 50% or more healing (P&lt;0.0001) as evaluated at six months, compared to 16% in 43 matched control wounds treated with standard-of-care.
The most common adverse events were observed in fewer than 5% of patients, including procedural pain and itch.
The Phase 1/2a study of Zevaskyn, which involved 38 chronic wounds across seven patients, showed that a single surgical application of Zevaskyn was associated with long-term improvement at treated sites over a median follow-up of 6.9 years, ranging from 4 to 8 years.
Last April, the FDA issued a Complete Response Letter (CRL) in response to the company&#8217;s Biologics License Application (BLA) for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38380100/fda-rejects-approval-of-abeona-therapeutics-skin-disorder-treatment-shares-sink" rel="noreferrer noopener">pz-cel for RDEB</a>.&nbsp;
The FDA noted that certain additional information&nbsp;was needed&nbsp;to&nbsp;satisfy Chemistry Manufacturing and Controls (CMC) requirements.&nbsp;
Price Action: ABEO stock is up 2.34% at $5.46 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides</a></li>
</ul>
Photo via Shutterstock

Health Care

General

ABEO

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy

Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Sleep Number will report an earnings per share (EPS) of $-0.05. 
Investors in Sleep Number are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 41.89% drop in the share price the next day.
Here's a look at Sleep Number's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.23</td>
<td>-0.17</td>
<td>-0.37</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.14</td>
<td>-0.22</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-42.0%</td>
<td>4.0%</td>
<td>20.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953405_0.png" alt="eps graph" />
<h3>Sleep Number Share Price Analysis</h3>
Shares of Sleep Number were trading at $7.4 as of April 28. Over the last 52-week period, shares are down 43.34%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SNBR/earnings">To track all earnings releases for Sleep Number visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNBR

Earnings Outlook For Sleep Number

Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Oatly Group to report an earnings per share (EPS) of $-0.84.
The market awaits Oatly Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $1.60, leading to a 37.69% increase in the share price on the subsequent day.
Here's a look at Oatly Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.4</td>
<td>-1.2</td>
<td>-1.4</td>
<td>-1.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3</td>
<td>-1.2</td>
<td>-1</td>
<td>-1.6</td>
</tr>
<tr>
<td>Price Change %</td>
<td>38.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953397_0.png" alt="eps graph" />
<h3>Tracking Oatly Group's Stock Performance</h3>
Shares of Oatly Group were trading at $10.0 as of April 28. Over the last 52-week period, shares are down 55.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OTLY/earnings">To track all earnings releases for Oatly Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OTLY

Oatly Group Earnings Preview

<ul>
<li>IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.</li>
<li>IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV.</li>
<li>IPH4502 showed strong preclinical activity across multiple tumor types, including triple-negative breast cancer, head and neck, and esophageal cancers, supporting its potential for broad clinical application.</li>
</ul>
Innate Pharma SA (PARIS:<a class="ticker" href="https://www.benzinga.com/stock/IPH#PARIS">IPH</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

IPHA

PARIS:IPH

Innate Pharma Presents New Preclinical Data For IPH4502 AACR Annual Meeting 2025; IPH4502 Shows Strong Preclinical Activity Across Multiple Tumor Types

Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Pulmonx will report an earnings per share (EPS) of $-0.40. 
Pulmonx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.12 in the last quarter, leading to a 32.23% increase in the share price on the following day.
Here's a look at Pulmonx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.45</td>
<td>-0.45</td>
<td>-0.42</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.36</td>
<td>-0.39</td>
<td>-0.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>32.0%</td>
<td>-8.0%</td>
<td>-6.0%</td>
<td>22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953386_0.png" alt="eps graph" />
<h3>Market Performance of Pulmonx's Stock</h3>
Shares of Pulmonx were trading at $5.19 as of April 28. Over the last 52-week period, shares are down 31.09%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LUNG/earnings">To track all earnings releases for Pulmonx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LUNG

Pulmonx's Earnings Outlook

<ul>
<li>Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies</li>
</ul>

Events

ABCL

AbCellera Presents Data For Preclinical Efficacy Of PSMA x CD3 T-Cell Engagers At AACR 2025

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Surmodics will report an earnings per share (EPS) of $-0.09. 
Investors in Surmodics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 4.06% drop in the share price on the subsequent day.
Here's a look at Surmodics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.33</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.13</td>
<td>-0.27</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953377_0.png" alt="eps graph" />
<h3>Tracking Surmodics's Stock Performance</h3>
Shares of Surmodics were trading at $31.1 as of April 28. Over the last 52-week period, shares are down 7.53%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Insights on Surmodics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Surmodics.
With 1 analyst ratings, Surmodics has a consensus rating of Buy. The average one-year price target is $43.0, indicating a potential 38.26% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Treace Medical Concepts, with an average 1-year price target of $9.17, suggesting a potential 70.51% downside.</li>
<li>Analysts currently favor an Buy trajectory for ClearPoint Neuro, with an average 1-year price target of $25.0, suggesting a potential 19.61% downside.</li>
<li>Analysts currently favor an Buy trajectory for Delcath Systems, with an average 1-year price target of $24.0, suggesting a potential 22.83% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surmodics</td>
<td>Buy</td>
<td>-2.06%</td>
<td>$13.56M</td>
<td>-3.17%</td>
</tr>
<tr>
<td>Treace Medical Concepts</td>
<td>Neutral</td>
<td>10.44%</td>
<td>$55.48M</td>
<td>-0.46%</td>
</tr>
<tr>
<td>ClearPoint Neuro</td>
<td>Buy</td>
<td>14.11%</td>
<td>$4.76M</td>
<td>-19.81%</td>
</tr>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>2701.48%</td>
<td>$12.97M</td>
<td>-8.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Surmodics ranks at the bottom for Revenue Growth and Gross Profit, with negative values compared to peers. However, it ranks at the top for Return on Equity, showing a positive performance in this metric. The Consensus rating for Surmodics is in line with one peer and higher than the other two.
<h3>Delving into Surmodics's Background</h3>
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
<h3>Unraveling the Financial Story of Surmodics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Surmodics's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.06%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Surmodics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -12.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surmodics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Surmodics's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SRDX/earnings">To track all earnings releases for Surmodics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SRDX

A Look at Surmodics's Upcoming Earnings Report

Standard Motor Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMP#NYSE">SMP</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Standard Motor Products to report an earnings per share (EPS) of $0.44.
The announcement from Standard Motor Products is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 0.38% drop in the share price on the subsequent day.
Here's a look at Standard Motor Products's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>1.11</td>
<td>0.78</td>
<td>0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.47</td>
<td>1.28</td>
<td>0.98</td>
<td>0.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953361_0.png" alt="eps graph" />
<h3>Standard Motor Products Share Price Analysis</h3>
Shares of Standard Motor Products were trading at $23.94 as of April 28. Over the last 52-week period, shares are down 26.14%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SMP/earnings">To track all earnings releases for Standard Motor Products visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Standard Motor Products's Quarterly Earnings

MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that MiMedx Group will report an earnings per share (EPS) of $0.05. 
MiMedx Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 1.62% increase in the share price the next day.
Here's a look at MiMedx Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.04</td>
<td>0.08</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.07</td>
<td>0.08</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>20.0%</td>
<td>-10.0%</td>
<td>19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953343_0.png" alt="eps graph" />
<h3>Tracking MiMedx Group's Stock Performance</h3>
Shares of MiMedx Group were trading at $6.83 as of April 28. Over the last 52-week period, shares are down 3.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on MiMedx Group</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MiMedx Group.
With 1 analyst ratings, MiMedx Group has a consensus rating of Outperform. The average one-year price target is $13.0, indicating a potential 90.34% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of CareDx, Vir Biotechnology and Iovance Biotherapeutics, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for CareDx, with an average 1-year price target of $30.33, suggesting a potential 344.07% upside.</li>
<li>Analysts currently favor an Buy trajectory for Vir Biotechnology, with an average 1-year price target of $58.2, suggesting a potential 752.12% upside.</li>
<li>Analysts currently favor an Buy trajectory for Iovance Biotherapeutics, with an average 1-year price target of $16.72, suggesting a potential 144.8% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for CareDx, Vir Biotechnology and Iovance Biotherapeutics, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MiMedx Group</td>
<td>Outperform</td>
<td>7.00%</td>
<td>$76.00M</td>
<td>3.98%</td>
</tr>
<tr>
<td>CareDx</td>
<td>Buy</td>
<td>32.04%</td>
<td>$58.40M</td>
<td>23.94%</td>
</tr>
<tr>
<td>Vir Biotechnology</td>
<td>Buy</td>
<td>17.45%</td>
<td>$10.59M</td>
<td>-8.75%</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>Buy</td>
<td>15189.21%</td>
<td>$28.15M</td>
<td>-10.59%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MiMedx Group ranks at the bottom for Revenue Growth and Gross Profit among its peers. However, it ranks at the top for Return on Equity.
<h3>Discovering MiMedx Group: A Closer Look</h3>
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin &amp; bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
<h3>MiMedx Group: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, MiMedx Group showcased positive performance, achieving a revenue growth rate of 7.0% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: MiMedx Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.01% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): MiMedx Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.93% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MiMedx Group's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MDXG/earnings">To track all earnings releases for MiMedx Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MDXG

A Peek at MiMedx Group's Future Earnings

MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that MediaAlpha will report an earnings per share (EPS) of $0.35.
The announcement from MediaAlpha is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.36, leading to a 18.49% drop in the share price on the subsequent day.
Here's a look at MediaAlpha's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.12</td>
<td></td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.17</td>
<td>0.07</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-18.0%</td>
<td>-17.0%</td>
<td>13.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<h3>Tracking MediaAlpha's Stock Performance</h3>
Shares of MediaAlpha were trading at $8.47 as of April 28. Over the last 52-week period, shares are down 58.78%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/MAX/earnings">To track all earnings releases for MediaAlpha visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: MediaAlpha's Earnings Outlook

Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Matthews International to report an earnings per share (EPS) of $0.38.
The market awaits Matthews International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.08, leading to a 9.93% drop in the share price on the subsequent day.
Here's a look at Matthews International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.22</td>
<td>0.38</td>
<td>0.55</td>
<td>0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.14</td>
<td>0.55</td>
<td>0.56</td>
<td>0.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>21.0%</td>
<td>-5.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953327_0.png" alt="eps graph" />
<h3>Tracking Matthews International's Stock Performance</h3>
Shares of Matthews International were trading at $20.68 as of April 28. Over the last 52-week period, shares are down 19.43%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MATW/earnings">To track all earnings releases for Matthews International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MATW

Earnings Preview: Matthews International

OneSpaWorld Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate OneSpaWorld Holdings to report an earnings per share (EPS) of $0.21.
Anticipation surrounds OneSpaWorld Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.01 in the last quarter, leading to a 7.96% drop in the share price on the following day.
Here's a look at OneSpaWorld Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.21</td>
<td>0.23</td>
<td>0.2</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.20</td>
<td>0.26</td>
<td>0.2</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953305_0.png" alt="eps graph" />
<h3>Tracking OneSpaWorld Holdings's Stock Performance</h3>
Shares of OneSpaWorld Holdings were trading at $17.24 as of April 28. Over the last 52-week period, shares are up 21.89%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OSW/earnings">To track all earnings releases for OneSpaWorld Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of OneSpaWorld Holdings's Earnings

Analyst Ratings

Press Releases

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Comments

Black Diamond Therapeutic

空売り

Black Diamond Therapeutic (NASDAQ:BDTX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル